Jenburkt Pharmaceuticals Ltd.

BSE: JENBURPH524731ISIN INE354A01013

Healthcare
Pharmaceuticals

Share price

₹930.00+30.00 (+3.33%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,317.00
52W low: ₹848.05
Off 52W high: -29.38%
1M return: +3.33%
3M return: -19.97%
6M return: -19.19%
1Y return: -26.32%
20D avg volume: 334
50 DMA: ₹960.35
200 DMA: ₹1,049.29

Key ratios Standalone

Market cap: ₹410.44 Cr
Current price: ₹930.00
52W high / low: ₹1,317.00 / ₹848.05
Face value: ₹10.00
P/E: 12.48
P/B: 2.60
EPS (TTM): ₹74.49
Book value / share: ₹357.69
ROE: 20.84%
ROCE: 23.20%
Operating margin: 31.60%
Net margin: 21.13%
Debt / equity: 0.00
Net debt: ₹-5.58 Cr
Interest cover: 102.13
Dividend yield: 2.23%
Dividend / share (TTM): ₹20.70
Payout: 27.79%
Cash conversion cycle: 64.7 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	48.32	35.51	44.63	43.02	45.56	35.53	41.05	36.89	41.22	32.54	38.84	35.66
	2.25	1.51	4.35	1.81	2.08	2.06	1.88	1.58	1.85	1.41	1.19	1.35
	50.57	37.03	48.98	44.84	47.64	37.58	42.93	38.48	43.07	33.94	40.03	37.01
	36.23	30.26	31.32	36.54	33.30	27.40	31.09	28.96	30.55	23.88	29.67	29.16
	1.96	2.32	2.19	2.47	2.19	2.14	2.28	2.24	2.15	1.84	2.52	2.15
	7.20	5.48	8.70	7.83	6.28	5.37	5.25	4.93	5.33	5.75	5.06	5.02
	14.87	13.03	9.52	14.71	13.93	11.72	11.43	10.92	12.52	10.67	10.38	11.56
	0.13	0.13	0.13	0.12	0.11	0.11	0.11	0.11	0.12	0.11	0.06	0.07
	0.80	0.64	0.81	0.83	0.74	0.72	0.79	0.78	0.64	0.52	0.62	0.63
	10.48	10.14	12.21	12.09	10.16	8.33	10.85	9.97	8.99	6.29	10.40	9.45
	14.34	6.77	17.66	8.30	14.33	10.18	11.84	9.51	12.52	10.06	10.37	7.84
	0.00	0.00	-3.95	0.00	0.00	0.00	0.00	—	—	—	—	—
	14.34	6.77	13.71	8.30	14.33	10.18	11.84	9.51	12.52	10.06	10.37	7.84
	4.13	0.88	2.86	2.37	4.17	2.39	3.30	3.01	2.92	2.65	2.48	2.44
	10.21	5.89	10.85	5.93	10.16	7.79	8.54	6.51	9.60	7.42	7.88	5.40
	23.13	13.34	24.58	13.44	23.03	17.66	19.34	14.75	21.75	16.80	17.86	12.25
Key metrics
	15.27	7.54	14.65	9.25	15.18	11.01	12.74	10.40	13.28	10.69	11.05	8.54
	31.60%	21.20%	32.80%	21.50%	33.30%	31.00%	31.00%	28.20%	32.20%	32.90%	28.50%	23.90%
	21.10%	16.60%	24.30%	13.80%	22.30%	21.90%	20.80%	17.60%	23.30%	22.80%	20.30%	15.10%
	6.90%	—	6.80%	—	7.70%	—	6.70%	—	—	—	—	—
	6.10%	-0.10%	8.70%	16.60%	10.50%	9.20%	5.70%	3.40%	—	—	—	—
	0.50%	-24.40%	27.00%	-8.90%	5.80%	5.00%	8.40%	20.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	171.48	168.74	151.69	141.97	136.75	123.98
	9.92	10.30	6.72	4.67	5.12	4.95
	181.42	179.04	158.41	146.63	141.87	128.93
	134.35	128.57	114.48	111.46	109.01	99.06
	8.94	8.99	8.51	8.39	11.12	11.74
	29.21	28.18	21.26	22.41	20.55	21.98
	52.13	49.88	45.54	42.49	38.81	36.49
	0.51	0.46	0.45	0.27	0.37	0.43
	3.08	3.11	2.73	2.34	2.26	1.90
	44.92	42.79	36.11	35.95	34.57	28.80
	47.07	50.47	43.93	35.18	32.87	29.87
	-3.95	-3.95	0.00	—	—	—
	43.12	46.52	43.93	35.18	32.87	29.87
	10.24	11.78	11.87	9.20	8.26	7.57
	32.88	34.74	32.06	25.98	24.61	22.30
	74.49	78.71	72.65	58.86	53.90	48.58
Key metrics
	46.71	50.09	47.11	37.79	35.50	32.20
	27.24%	29.70%	31.10%	26.60%	26.00%	26.00%
	19.17%	20.60%	21.10%	18.30%	18.00%	18.00%
	—	23.20%	25.00%	—	—	—
	7.83%	11.20%	6.80%	3.80%	10.30%	—
	-0.36%	8.40%	23.40%	5.60%	10.40%	—
	—	12.80	8.20	—	—	—
	—	0.76	0.87	—	—	—
	—	0.00	0.01	—	—	—
	—	-5.58	-5.38	—	—	—
	—	64.7	51.7	—	—	—
Balance sheet
	—	226.01	196.19	—	—	—
	—	95.09	56.53	—	—	—
	—	5.58	7.36	—	—	—
	—	24.36	20.73	—	—	—
	—	13.63	8.88	—	—	—
	—	3.37	1.66	—	—	—
	—	19.22	14.43	—	—	—
	—	8.10	8.16	—	—	—
	—	23.15	18.82	—	—	—
	—	0.00	1.98	—	—	—
	—	0.00	1.98	—	—	—
	—	0.00	0.00	—	—	—
	—	197.04	171.78	—	—	—
Cash flow
	—	26.52	27.91	—	—	—
	—	-19.45	-17.04	—	—	—
	—	-8.86	-7.62	—	—	—
	—	13.72	19.71	—	—	—

Compounded growth

Sales CAGR 3Y: +7.26%
Sales CAGR 5Y: —
Profit CAGR 3Y: +12.18%
Profit CAGR 5Y: —
Sales YoY (TTM): +7.83%
Profit YoY (TTM): -0.36%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 46.62%

Quarter	September 2026	June 2026
Promoter %	46.62%	46.62%

Holder	Type	Holding	Previous	Change
ASHISH UTTAM BHUTA	Promoter	18.07%	18.07%	0.00%
BHUTA HOLDINGS PRIVATE LIMITED	Promoter	13.96%	13.96%	0.00%
KALINDI HEMENDRA BHUTA	Promoter Group	9.06%	9.06%	0.00%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY	Public	2.31%	2.32%	-0.01%
NILAY DAGA	Public	1.72%	—	—
VARUN DAGA	Public	1.72%	1.03%	+0.69%
NIRAJ DAGA	Public	1.72%	—	—
SHREANS DAGA	Public	1.72%	—	—
KAUSHIK DAGA	Public	1.72%	1.02%	+0.70%
RANJEET SINGH SIBIA	Public	1.50%	1.50%	0.00%
OPTIRATIONAL VENTURES LLP	Public	1.18%	1.20%	-0.02%
BHAVIKA ASHISH BHUTA	Promoter Group	1.17%	1.17%	0.00%
KUNTI KETAN GALA	Promoter Group	1.16%	1.16%	0.00%
RAJIV GARG	Public	1.07%	1.07%	0.00%
BHARAT C JAIN	Public	1.02%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Jenburkt Pharmaceuticals Ltd. S	410	930.00	12.48	23.20%	+7.83% TTM	-0.36% TTM	-26.32%

Filings & corporate actions

Recent announcements

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd4 Nov 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Newspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September, 2026.4 Nov 2026 · Company Update / Newspaper Publication
Outcome of the Board Meeting held today on 03rd November, 2026.3 Nov 2026 · Board Meeting / Outcome of Board Meeting
Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026.3 Nov 2026 · Result / Financial Results
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone Unaudited ....29 Oct 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd12 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.12 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.22 Sep 2026 · Company Update / General
Intimation of closure of trading window of the Jenburkt Pharmaceuticals Limited as per the SEBI(Prohibition of Insider Trading) Regulations, 2015.22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation about Resignation of a Senior Management Personnel of the Company.18 Sep 2026 · Company Update / Change in Management
Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027 to 31st March, 2032, Approved with requisite ....4 Sep 2026 · Company Update / Change in Directorate
Submission of consolidated Voting Results and Scrutinizer''s Report on all the Resolutions as set out in the Notice Convening the 41st AGM of the Company held on 04th September, 2026.4 Sep 2026 · AGM/EGM / AGM
Proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.4 Sep 2026 · Company Update / General
Summary of the proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.4 Sep 2026 · AGM/EGM / AGM
Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015, we hereby inform you about the change in Senior Manaaement ....4 Sep 2026 · Company Update / Change in Management
Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.7 Aug 2026 · Company Update / Newspaper Publication
Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.6 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting held today on 06th August, 2026.6 Aug 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.4 Aug 2026 · Company Update / Newspaper Publication
Notice of the 41st Annual General Meeting of the Company Schedule to be held on Friday, 04th September, 2026, through VC/OAVM.3 Aug 2026 · AGM/EGM / AGM
Submission of the Annual Report for the FY 2025-26, containing Audited Standalone Financial Statements, Auditors Report and Directors Report and the Notice convening 41st Annual General ....3 Aug 2026 · Others / Reg. 34 (1) Annual Report
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve standalone unaudited ....29 Jul 2026 · Board Meeting / Board Meeting
Intimation of shifting of Registered Office of the Company within the local limits of city of Mumbai.13 Jul 2026 · Company Update / Change in Registered Office Address
Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 30th June, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window of Jenburkt Pharmaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations, 2015.18 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.27 May 2026 · Company Update / Newspaper Publication
Annual Secretraial Compliance Report for the financial year ended 31st March, 2026.7 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
The Company has fixed Friday, 28th August, 2026, as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during ....6 May 2026 · Corp. Action / Record Date
Newspaper Publication for standalone Audited financial results for the quarter and financial year ended on 31st March, 2026.6 May 2026 · Company Update / Newspaper Publication
The Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26, Subject ....5 May 2026 · Corp Action / Dividend Updates
Re-appointment of Whole Time Director and CFO of the Company, subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.5 May 2026 · Company Update / Change in Management
Standalone audited financial reults of the Company for the quarter and financial year ended on 31st March, 2026.5 May 2026 · Result / Financial Results
Outcome of Board Meeting Held on 05th May, 2026.5 May 2026 · Board Meeting / Outcome of Board Meeting
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve the audited results ....28 Apr 2026 · Board Meeting / Board Meeting
Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as ....14 Apr 2026 · Company Update / General
Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.7 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of trading window of Jenburkt Phamaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations, 2015.23 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication for Unaudited statndalone financial Statement for the quarter and nine months ended on 31st Decemeber, 2025.4 Feb 2026 · Company Update / Newspaper Publication
Standalone Unaudited financial results for the quarter and nine months ended on 31st December, 2025.3 Feb 2026 · Result / Financial Results
Outcome of the Board Meeting held today on 03rd February, 2026.3 Feb 2026 · Board Meeting / Outcome of Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 20.7000	28 Aug 2026	28 Aug 2026	—
Final Dividend - Rs. - 18.0000	11 Jul 2025	11 Jul 2025	—
Dividend - Rs. - 15.3000	23 Jul 2024	—	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results